Catalent Inc (NYSE:CTLT) traded down 6.7% during trading on Monday . The company traded as low as $43.10 and last traded at $43.50. 2,355,965 shares traded hands during trading, an increase of 180% from the average session volume of 841,957 shares. The stock had previously closed at $46.60.
A number of equities research analysts recently commented on the company. Royal Bank of Canada reaffirmed a “buy” rating and set a $48.00 price objective on shares of Catalent in a research note on Monday. Zacks Investment Research raised Catalent from a “hold” rating to a “buy” rating and set a $48.00 price objective for the company in a research note on Monday, November 6th. BidaskClub cut Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. Goldman Sachs Group assumed coverage on Catalent in a research note on Wednesday, January 24th. They set a “buy” rating and a $50.00 price objective for the company. Finally, Piper Jaffray Companies lifted their price objective on Catalent from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 7th. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $45.20.
The company has a debt-to-equity ratio of 2.01, a current ratio of 2.91 and a quick ratio of 2.49. The company has a market cap of $6,191.25, a price-to-earnings ratio of 50.00, a price-to-earnings-growth ratio of 2.94 and a beta of 1.47.
Catalent (NYSE:CTLT) last posted its earnings results on Monday, February 5th. The company reported $0.45 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.33 by $0.12. The firm had revenue of $606.30 million for the quarter, compared to analyst estimates of $565.05 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The company’s revenue for the quarter was up 25.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.27 earnings per share. sell-side analysts forecast that Catalent Inc will post 1.48 earnings per share for the current fiscal year.
In other Catalent news, Director Uwe Roehrhoff bought 7,500 shares of Catalent stock in a transaction on Tuesday, November 21st. The shares were purchased at an average cost of $39.22 per share, for a total transaction of $294,150.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. Insiders own 1.70% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Catalent by 3.8% in the second quarter. Vanguard Group Inc. now owns 10,119,431 shares of the company’s stock valued at $355,192,000 after purchasing an additional 369,526 shares in the last quarter. State Street Corp lifted its holdings in shares of Catalent by 10.7% in the second quarter. State Street Corp now owns 4,315,841 shares of the company’s stock valued at $151,488,000 after purchasing an additional 418,196 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Catalent by 755.3% in the fourth quarter. American Century Companies Inc. now owns 2,631,643 shares of the company’s stock valued at $108,108,000 after purchasing an additional 2,323,971 shares in the last quarter. Earnest Partners LLC lifted its holdings in shares of Catalent by 0.5% in the third quarter. Earnest Partners LLC now owns 2,570,156 shares of the company’s stock valued at $102,601,000 after purchasing an additional 12,652 shares in the last quarter. Finally, Macquarie Group Ltd. lifted its holdings in shares of Catalent by 15.8% in the third quarter. Macquarie Group Ltd. now owns 2,069,323 shares of the company’s stock valued at $82,607,000 after purchasing an additional 282,559 shares in the last quarter. Institutional investors own 98.86% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.thestockobserver.com/2018/02/05/catalent-ctlt-shares-down-6-7.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.